American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer

Debbie Saslow(American Cancer Society), Diane Solomon(National Institutes of Health), Herschel W. Lawson(Emory University), Maureen Killackey(Memorial Sloan Kettering Cancer Center), Shalini Kulasingam(University of Minnesota), Joanna M. Cain(University of Massachusetts Chan Medical School), Francisco García(University of Arizona), Ann Moriarty, Alan G. Waxman(University of New Mexico), David C. Wilbur(Harvard University), Nicolas Wentzensen(National Institutes of Health), Levi S. Downs(University of Minnesota Medical Center), Mark Spitzer(Cornell University), Anna‐Barbara Moscicki, Eduardo L. Franco(McGill University), Mark H. Stoler(University of Virginia Health System), Mark Schiffman(National Institutes of Health), Philip E. Castle(Diagnostics for the Real World (United States)), Evan R. Myers(Duke Medical Center)
CA A Cancer Journal for Clinicians
March 14, 2012
10.3322/caac.21139
Cited by 1,397Open Access
Full Text

Abstract

An update to the American Cancer Society (ACS) guideline regarding screening for the early detection of cervical precancerous lesions and cancer is presented. The guidelines are based on a systematic evidence review, contributions from 6 working groups, and a recent symposium cosponsored by the ACS, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology, which was attended by 25 organizations. The new screening recommendations address age-appropriate screening strategies, including the use of cytology and high-risk human papillomavirus (HPV) testing, follow-up (eg, the management of screen positives and screening intervals for screen negatives) of women after screening, the age at which to exit screening, future considerations regarding HPV testing alone as a primary screening approach, and screening strategies for women vaccinated against HPV16 and HPV18 infections.

Related Papers

Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America
Jonathan E. Kaplan, Constance A. Benson, King K. Holmes et al.|PsycEXTRA Dataset|2009|1.4k
The Pap Test and Bethesda 2014
Ritu Nayar, David C. Wilbur|Journal of the American Society of Cytopathology|2015|1.1k
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication
Ni Li, Silvia Franceschi, Rebecca Howell‐Jones et al.|International Journal of Cancer|2010|1.1k
Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer
Pontus Nauclér, Walter Ryd, Sven Törnberg et al.|New England Journal of Medicine|2007|806
American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors
Debbie Saslow, Philip E. Castle, J. Thomas Cox et al.|CA A Cancer Journal for Clinicians|2007|527